{"result": "(\"entity\"<|>ADRENOLEUKODYSTROPHY<|>EVENT<|>Adrenoleukodystrophy is a genetic disorder that affects the nervous system and adrenal glands, characterized by the accumulation of very long-chain fatty acids in the body.)\n##\n(\"entity\"<|>ADRENOMYELONEUROPATHY<|>EVENT<|>Adrenomyeloneuropathy is a condition related to adrenoleukodystrophy, primarily affecting the spinal cord and peripheral nerves.)\n##\n(\"entity\"<|>LORENZO'S OIL<|>EVENT<|>Lorenzo's Oil is a dietary therapy used in the treatment of adrenoleukodystrophy, aimed at reducing the levels of very long-chain fatty acids in the body.)\n##\n(\"entity\"<|>JOHN HOPKINS MEDICAL JOURNAL<|>ORGANIZATION<|>John Hopkins Medical Journal is a publication that features research and clinical studies, including those related to adrenoleukodystrophy.)\n##\n(\"entity\"<|>NEJM<|>ORGANIZATION<|>The New England Journal of Medicine (NEJM) is a prestigious medical journal that publishes research articles, including studies on treatments for adrenoleukodystrophy.)\n##\n(\"entity\"<|>MOSER HW<|>PERSON<|>Moser HW is a researcher who has contributed significantly to the study and treatment of adrenoleukodystrophy.)\n##\n(\"relationship\"<|>ADRENOLEUKODYSTROPHY<|>ADRENOMYELONEUROPATHY<|>Adrenomyeloneuropathy is a condition that is related to and often occurs in conjunction with adrenoleukodystrophy<|>7)\n##\n(\"relationship\"<|>ADRENOLEUKODYSTROPHY<|>LORENZO'S OIL<|>Lorenzo's Oil is a treatment specifically designed for managing the symptoms of adrenoleukodystrophy<|>8)\n##\n(\"relationship\"<|>MOSER HW<|>ADRENOLEUKODYSTROPHY<|>Moser HW has conducted significant research on adrenoleukodystrophy, contributing to its understanding and treatment<|>9)\n##\n(\"relationship\"<|>JOHN HOPKINS MEDICAL JOURNAL<|>ADRENOLEUKODYSTROPHY<|>John Hopkins Medical Journal publishes research articles related to adrenoleukodystrophy, contributing to the medical community's understanding of the disorder<|>6)\n##\n(\"relationship\"<|>NEJM<|>ADRENOLEUKODYSTROPHY<|>NEJM publishes studies and clinical trials related to adrenoleukodystrophy, providing valuable insights into its treatment<|>6)\n##\n(\"relationship\"<|>LORENZO'S OIL<|>NEJM<|>NEJM has published research on the efficacy of Lorenzo's Oil as a treatment for adrenoleukodystrophy<|>7)\n<|COMPLETE|>", "input": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: of adrenoleukodystrophy and adrenomyeloneuropathy. J Neuropathol Exp Neurol 1995; 54 (5): 740-745.\n\n7. Powers JM. Adrenoleukodystrophy. Clin Neuropathol 1985; 4: 181-199.\n\n8. Powers JM, Liu Y, Moser A, Moser H. The inflammatory myelinopathy of adrenoleukodystrophy: cells, effector molecules and pathogenic implication. J Neuropathol Exp Neurol 1992; 51: 630-643.\n\n9. Igarashi M, Shaumburg HH, Powers J, Kishimoto Y, Kolodny E, Suzuki K. Fatty acid abnormality in adrenoleukodystrophy. J Neurochem 1976; 26: 851-860.\n\n10. Knazek RA, Rizzo WB, Schulman JD, Dave JR. Membrane microviscosity is increased in the erythrocytes of patients with adrenoleukodystrophy and adrenomyeloneuropathy. J Clin Invest 1983; 72: 245-248.\n\n11. Kishimoto Y, Moser HW, Kawamura N, Platt M, Pallante B, Fenselau C. Evidence that abnormal very long chain fatty acids of brain cholesterol esters are of exogenous origin. Biochem Byophys Res Commun 1980; 96: 69-76.\n\n12. Van Duyn MA, Moser AM, Brown FR, Sacktor N, Liu A, Moser HW. The design of a diet restricted in saturated very long chain fatty acids: therapeutical application in adrenoleukodystrophy. Am J Clin Nutr 1984; 40: 277-284.\n\n13. Moser HW, Pallante SL, Moser AE, Rizzo WB, Shulman J, Fenselau C. Adrenoleukodystrophy: origin of very long chain fatty acids and therapy. Pediatr Res 1983; 17: 293.\n\n14. Brown FR, Van Duyn MA, Moser AB, Shulman JD, Rizzo W. Adrenoleukodystrophy: effects of dietary restriction of very long chain fatty acids and administration of carnitine and clofibrate in Clinical sta-\n---\n## BLOQUE: LÍPIDOS\n\ntus and plasma fatty acids. John Hopkins Med J 1982; 151: 164-172.\n\n15. Rizzo WB, Watkins PA, Phillips MW, Cranin D, Campbell B, Avigan J. Adrenoleukodystrophy: oleic acid lowers fibroblast saturated C22-C26 fatty acids. Neurology 1986; 36: 357-361.\n\n16. Moser AB, Borel J, Odone A, Naidu S, Cornblath D. A new dietary therapy for adrenoleukodystrophy: biochemical and preliminary Clinical results in 36 patients. Ann Neurol 1987; 21: 240-249.\n\n17. Rizzo WB, Phillips MW, Dammann AL, Leshner RY, Jannings SVK. Adrenoleukodystrophy: dietary oleic acid lowers hexacosanoate levels. Ann Neurol 1987; 21: 232-9.\n\n18. Moser HW. Treatment of X-linked adrenoleukodystrophy with Lorenzo's oil. J Neurol Neurosurg Psychiatry 1999; 67:270-90.\n\n19. Aubourg P, Adamsbaum C, Lavallard M, Rocchiccioli F, Jambaque I, Jakobezak C et al. Two year-trial of oleuc and erucic acids (Lorenzo's oil) as treatment for adrenoleukodystrophy. NEJM 1993; 329: 745-52.\n\n20. Val Geel BM, Assies J, Haverkort EB. Progression of abnormalities in adrenomyeloneuropathy and neurologically asymptomatic x-linked adrenoleukodystrophy despite treatment with Lorenzo's oil. J Neurol Neurosurg Psychiatry 1999; 67: 290-9.\n\n21. Konijnenberg A, Van Geel BM, Sturk A, Schaap MCL, Von Dem Borne AEG, De Bruijne LG et al. Lorenzo's oil and platelet activation in adrenomyeloneuropathy and asymptomatic x-linked adrenoleukodystrophy. Platelets 1988; 9: 41-8.\n\n22. Mosser HW, Mosser AB, Hollandsworth K, Brereton NH, Raymond GV. «Lorenzo's oil» therapy for X-kinked adrenoleukodystrophy: rationale and current assessment of efficacy. J Mol Neurosci 2007; 33: 105-13.\n\n23. Krivit W, Peters C, Shapiro EG. Bone marrow transplantation as effective treatment of central nervous system disease in globoid cell leukodystrophy,meta-chromatic leukodystrophy, adrenoleukodystrophy, mannosidosis, fucosidosis, aspartylglucosa-minuria, Hurler, Maroteaux-Lamy and Sly síndromes and gaucher disease type III. Curr Opin Neurol 1999; 12: 167-176.\n\n24. Moser HW. Therapy of X-linked adrenoleukodystrophy. Neuro Rx 2006; 3: 246-253.\n\n25\n######################\nOutput:", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": null}